INSMED PROVIDES UPDATE ON IPLEX TRIAL DATA

Insmed recently provided an update on its ongoing clinical trial of iPlex (Mecasermin rinfibate) for the treatment of children with growth failure who suffer from Severe Primary IGF-1 (insulin-like growth factor-1) deficiency (Primary IGFD).

Some of these data were recently featured in a podium presentation at the European Society of Pediatric Endocrinology/Lawson Wilkins Pediatric Endocrine Society's 7th Joint Meeting. The data demonstrated that as a once-daily IGF-1 therapy, iPlex safely and significantly increased height velocity, the primary endpoint of the study, in children with short stature due to Primary IGFD.

IPlex is a proprietary drug product for the delivery of recombinant insulin-like growth factor 1. It is administered as a preformed complex with a recombinant form of its natural binding protein, insulin-like growth factor binding protein 3. The novel compound is administered as a subcutaneous injection, which can restore and maintain IGF-1 levels to physiologically relevant levels.